|
|
| 날짜 |
2010-12-02 |
|
|
| 제목 |
Clinica Medtech Intelligence |
|
|
| 내용 |
Clinica
Contents
Headlines
454 Life Sciences and Roche Diagnostics to merge in $155m deal
454 Life Sciences the Branford Connecticutt DNA-sequencing technology developer is to be
Boost for breast MRI as trial shows improved diagnosis rates
Breast MRI in women already diagnosed with cancer in one breast can detect over 90% of tumours that are missed by mammography and clinical breast examination in the opposite (contralateral) breast according to a study published in the March 29 issue of The New England Journal of Medicine (NEJM).
Clinical Data and Roche sign high-throughput sequencing services deal
Roche Diagnostics and Clinical Data today announced an agreement to co-market a range of genome sequencing services using a 454 Genome Sequencer FLX (GS FLX) system to be installed at one of the European facilities of Clinical Data's Cogenics division. The GS FLX developed by 454 Life Sciences of Branford Connecticutt promises a state-of-the-art high-throughput operation.
UK document explains regulatory decisions
The UK's Healthcare and Regulatory products Agency the MHRA is inviting comments on a document it is drafting that sets out how regulatory decisions are made about medicines and medical devices. In the light of these comments it will publish a revised version in the summer of 2007.
XDR (extensively drug-resistant) TB recorded in the UK in 2005
Clinica has received confirmation from the UK's Health Protection Agency (HPA) that three cases of extensively drug-resistant (XDR) TB were recorded in the UK in 2005 as defined at the time but that no cases have been recorded under the recently revised case definition a spokesperson said. Almost 8200 new cases of TB were reported in England Wales and Northern Ireland in 2006 (up 2% on 2005) according to provisional data released last week.
관련URL : http://www.pjbpubs.com/cms.asp?pageid=746
|
|
|
